AstraZeneca PLC AZN
LSE · United Kingdom · Health Technology
GBp 12,120.00-160.00 (-1.30%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The shares fell more than major US indexes, while Zacks consensus estimates point to lower quarterly earnings and higher revenue.
Summit gained after AstraZeneca agreed to invest $2 billion, while CarMax beat earnings forecasts and FICO faced a new scoring framework.
Investors marked down Olema after AstraZeneca’s SERENA-4 setback raised fresh questions about oral SERD drugs in breast cancer.